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Human beta-defensins (hBDs) are antimicrobial peptides of human innate immunity. The antibacterial
activities of hBDs 1, 2, and 4 but not the activity of hBD3 are impaired by high salt levels. We have designed
and synthesized seven novel hBD analogs, constituted by different domains of hBD1 (which is constitutively
expressed in humans) and of hBD3 (which is induced by microorganisms and inflammatory factors in
humans), that would maintain and potentially increase the wild-type antimicrobial activities and be salt
resistant. We have compared the antibacterial, antiviral, and chemotactic activities of the analogs with those
of hBD1 and hBD3. We show that the hBD1 internal region and the hBD3 C-terminal region are critical for
antibacterial activity also at high salt concentrations, whereas deletion of the N-terminal region of hBD3
results in an increase in antibacterial activity. All analogs inhibited herpes simplex virus; antiviral activity was
enhanced by the hBD1 internal region and the hBD3 C-terminal region. Wild-type and analog peptides were
chemotactic for granulocytes and monocytes, irrespective of the salt concentrations. These new peptides may
have therapeutic potential.
Beta-defensins (BDs) are highly conserved small peptides
produced by plants, invertebrates, and vertebrates that de-
veloped as part of the primordial immune protective mech-
anism (19). Four of these peptides, called human BD1
(hBD1; DEFB1), hBD2 (DEFB4), hBD3 (DEFB103A), and
hBD4 (DEFB104), are mainly expressed by respiratory, gas-
trointestinal, and urogenital epithelial cells either constitu-
tively (hBD1) or after induction by microorganisms or inflam-
matory factors (hBD2 to hBD4) (19). All four hBDs are
cationic and 36 to 45 amino acids long and show similar folding
and an invariable six-cysteine motif that gives rise to three
disulfide bonds (2, 11, 12, 25, 26).
Human beta-defensins 1 to 4 exert different bactericidal and
antiviral activities against various pathogens (8, 15, 27). The
antibacterial effects of hBD1 (9), hBD2 (33), and hBD4 (5) are
attenuated by high NaCl concentrations, such as those in the
airway surface fluid of patients with cystic fibrosis (CF) (21,
29). Human beta-defensin 3 can withstand NaCl concentra-
tions as high as 150 mM, thanks to its peculiar structural
characteristics and charge (10). In the field of viral diseases,
hBD2 and -3 inhibit human immunodeficiency virus (HIV)
type 1 (HIV-1) replication and virion infectivity (20, 31) and
modulate HIV-1 coreceptor expression (20). Human herpes
simplex virus (HSV) type 1 (HSV-1), HSV-2, and other viruses
preincubated with alpha human neutrophil peptide 1 (hNP1)
to hNP3 (6, 28) or theta (37) defensins lose their ability to
infect target cells (28). As yet, there are no data on the effect
of hBDs on HSV-1 and -2. In addition to direct antimicrobial
activity, hBDs also exert chemotactic activity: hBD1, -2, and -3
are chemotactic for monocytes and dendritic and T cells. Hu-
man beta-defensin 3 is the only beta-defensin chemotactic for
macrophages (4, 18, 19), whereas the chemotactic effect of
hBDs on granulocytes has yet to be elucidated (4, 18).
The two natural defensins hBD1 and hBD3 were chosen for
use in the experiments described in this paper for the following
reasons: hBD1 is constitutively expressed but its antibacterial
activity is greatly impaired by NaCl, while hBD3 is insensitive
to salt. Thus, we designed and synthesized hBD analogs that, in
principle, would maintain the antibacterial and antiviral activ-
ities of hBD1 and possess a resistance capability in the pres-
ence of high NaCl concentrations, like hBD3 does. We then
compared the antibacterial, chemotactic, and antiviral activi-
ties of the novel synthetic analogs with those of wild-type hBD1
and hBD3. Our data show that some of the synthetic analogs
have higher antimicrobial activity than the wild type, also at
high NaCl concentrations.
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MATERIALS AND METHODS
Peptide design. The beta-defensin sequences used in this study were taken
from the SWISS-Prot database. Graphics analyses were run on a Silicon Graph-
ics Indigo2 workstation. The InsightII/Discover program (Biosym Technologies,
San Diego, CA) was used to compare the structures of the beta-defensin mole-
cules obtained from the Protein Data Bank (Brookhaven National Laboratory,
Upton, NY). Structural parameters, such as net positive charge, hydrophobicity,
and the hydrophobic moment, and the analysis of the hydrophobic moment/
hydrophilic moment ratio were also evaluated in order to design new analogs
that could have enhanced activity.
Peptide synthesis. Peptides were synthesized by the standard solid-phase 9-flu-
orenylmethoxycarbonyl (Fmoc) method. NovaSyn TGA (Merck, Darmstadt,
Germany) resin (substitution, 0.25 mmol/g) was used as solid-phase support, and
syntheses were performed on a scale of 100 mol. Ten equivalents of the first
amino acid were coupled on the resin according to the N,N-diisopropylcarbo-
diimide (DIC)/4-dimethylaminopyridine (DMAP) method (with 10 equivalents
of Fmoc-amino acid, 5 equivalents of DIC, 0.1 equivalent of DMAP). All suc-
cessive amino acids, 4 equivalents relative to the resin loading, were coupled by
using 1 equivalent of Fmoc-amino acid, 1 equivalent of 2-(1H-benzotriazole-1-yl)-
1,1,3,3-tetramethyluronium tetrafluoroborate, 1 equivalent of N-hydroxybenzotri-
azole (HOBT; 0.5 mM HOBT in N-methylpyrrolidone [NMP]) and 2 equivalents
of N,N-diisopropylethylamine (DIPEA; 1 mM DIPEA in NMP). The Fmoc
protecting group was removed with 30% (vol/vol) piperidine in NMP. The
peptides were fully deprotected and cleaved from the resin with trifluoroacetic
acid (TFA) with 5% thioanisole, 3% ethandithiol, and 2% anisole as scavengers.
The crude peptides were precipitated with ice-cold ethyl ether, filtered, dissolved
in water, lyophilized, and reduced with dithiothreitol (DTT). The peptides were
purified to homogeneity by preparative reverse-phase high-pressure liquid chro-
matography (RP-HPLC). The samples were injected on a Phenomenex (Tor-
rance, CA) C18 column (22 mm by 25 cm, 5 mm) eluted with an H2O–0.1% TFA
(solvent A) and CH3CN–0.1% TFA (solvent B) solvent mixture. A linear gra-
dient from 5 to 50% solvent B over 17 min at a flow rate of 20 ml/min was used.
The collected fractions were lyophilized to dryness and analyzed by analytical
RP-HPLC on a Shimadzu class LC10 column equipped with a diode array
detector (SPD-M10AV) and by use of a Phenomenex C18 analytical column (4.6
by 250 mm, 5 mm). The identity and the oxidation state of the purified peptides
were confirmed by electron spray ionization liquid chromatography-mass spec-
trometry (ESI LC-MS) with a Thermo electron MSQ surveyor. The peptides
were dissolved in phosphate-buffered saline (PBS) for all experiments.
Folding and disulfide formation. Oxidation in 20% dimethyl sulfoxide
(DMSO) was performed by dissolving samples in 0.1 M Tris HCl (pH 8.2)–1 mM
EDTA at a peptide concentration of 1 mM. The folding reaction was monitored
by RP-HPLC at 8, 16, and 48 h. The folded product was analyzed and purified,
and its molecular mass was determined by LC-MS.
CD measurements. Circular dichroism (CD) spectra were recorded with a
Jasco J-715 spectropolarimeter in a 0.1-cm quartz cell at room temperature. The
spectra of reduced and oxidized hBD1 (0.1 mM) and hBD3 and of reduced
analogs 1C and 3I were obtained in 5 mM HEPES buffer at pH 7.5 in the
presence or the absence of 40% trifluoroethanol (TFE). The spectra were the
averages of three consecutive scans from 250 to 195 nm, recorded with a band-
width of 3 nm, a time constant of 16 s, and a scan rate of 10 nm/min. The spectra
were recorded and corrected for the blank.
Antibacterial activity assay. A CFU assay of the antibacterial activities of the
hBDs against Pseudomonas aeruginosa ATCC 27853 (American Type Culture
Collection, Manassas, VA), Enterococcus faecalis ATCC 29212, and Escherichia
coli ATCC 25922 was performed. The strains were grown under aerobic condi-
tions in tryptic soy broth (Difco Laboratories, Detroit, MI) at 37°C and incubated
in the presence of the hBDs for 2 h at 37°C. We used two concentrations of
peptides, i.e., 2.5 M, at which 100% of the P. aeruginosa strains were killed by
wild-type hBD3 (minimal bactericidal concentration [MBC]), and 12.5 M. For
the salt dependence assay, NaCl was included in the incubation buffer over a
range of concentrations potentially present in the airway surface fluid of healthy
subjects and patients with CF (20), i.e., 0, 50, 100, and 200 mM NaCl. Each assay
was performed in triplicate. Bactericidal activity (the mean and standard devia-
tion [SD] of three assays) was expressed as the ratio between the number of
colonies counted and the number of colonies on a control plate. The MICs of the
wild-type peptides and their analogs were determined by use of a modified
version (3a) of the broth microdilution assay of the National Committee for
Clinical Laboratory Standards with a final inoculum of 105 CFU/ml. The follow-
ing peptide concentrations were used: 100, 50, 25, 12.5, 6.25, 3.12, and 1.56 M.
Antiviral activity. Vero cells were grown in Dulbecco’s modified Eagle’s me-
dium (DMEM) supplemented with 10% fetal calf serum. HSV-1 carrying a lacZ
gene driven by the cytomegalovirus (CMV) immediate-early 1 promoter to
express beta-galactosidase was propagated as described previously (7). All ex-
periments were conducted in parallel with no-peptide controls. To assess the
effects of the peptides on the inhibition of HSV infectivity, we treated cell
monolayers as follows. (i) For the coexposure experiments, the cells were incu-
bated with increasing concentrations of the peptides (1, 5, 10, 20, 50, 100, and 250
M) and with the viral inoculum for 45 min at 37°C. Nonpenetrated viruses were
inactivated by citrate buffer at pH 3.0. Monolayers were fixed and stained with
5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-gal), and the plaque
numbers were scored. The experiments were performed in triplicate, and the
percent inhibition was calculated with respect to the number of plaques in the
no-peptide control experiments. (ii) For the virus preexposure experiments,
approximately 2  104 PFU of HSV-1 was incubated in the presence of 20 M
peptides for 45 min at 37°C and then titrated on Vero cell monolayers. (iii) For
the cell preexposure experiments, Vero cells were incubated with 20 M
peptides for 30 min at 4°C and infected with serial dilutions of HSV-1 for 45
min at 37°C.
Preparation of leukocytes. Monocytes and neutrophils were isolated as de-
scribed in the StemSep Cell Technical Manual (30a). Neutrophils were purified
from lysed buffy coats by use of a StemSep negative selection system. Cell
viability was assessed by analysis of the light-scatter properties, and the cells were
counted by use of a logical gate strategy based on Trucount tubes (Becton
Dickinson) before and after the negative selection.
Measurement of leukocyte migration. The chemotaxis assay of monocytes and
neutrophils (90 to 95% purity) was performed in 96-well disposable chemotaxis
chambers (Neuroprobe, Gaithersburg, MD) with polyvinylpyrrolidone-free poly-
carbonate membranes (pore sizes, 8 mm for monocytes and 5 mm for neutro-
phils). Chemotaxis was measured by use of the calcein fluorescence signal, and
the results were read in a microplate fluorescence reader (Victor 3 1420 multi-
label counter; Perkin-Elmer). We calculated the migration index as the ratio
between the sample mean fluorescence (after subtraction of the negative-control
mean fluorescence)/positive-control mean fluorescence. Each assay was per-
formed in triplicate.
Toxicity. We assessed the cytotoxicities of wild-type hBDs and analogs on
neutrophils and monocytes at different concentrations (i.e., 2.5 and 12.5 M) and
on Vero cells, also at different concentrations (i.e., 10 to 500 M), by a lactate
dehydrogenase assay, which was carried out according to the manufacturer’s
instructions by use of a cytotoxicity detection kit (Roche Diagnostic, Milan,
Italy).
Statistical methods. All data are summarized by using the mean and the
standard deviation computed for three independent replicates. Differences in
means were tested by the two-tailed unpaired or paired t test, as appropriate.
RESULTS
Structural features of wild-type peptides hBD1 and hBD3.
To identify the domains responsible for the antibacterial, an-
tiviral, and chemotactic effects of hBD1 and hBD3, we looked
for differences in their structures. Superimposition of the
three-dimensional structures of hBD1 and hBD3 showed dif-
ferences between the two molecules in the N-terminal region,
the C-terminal region, and the internal domain between the
third and the fourth Cys residues (Fig. 1A to C). In particular,
the N-terminal helix in hBD3 starts from Lys8, whereas resi-
dues 1 to 7 are disordered. Furthermore, the N-terminal helix
in hBD3 is strongly connected to the  sheet with several van
der Waals contacts between Ile30 and Tyr10, whereas there are
no strong, well-defined interactions in hBD1. The N-terminal
region of hBD3 has four positive charges (Lys8, Arg12, Arg14,
and Arg17) that are lacking in hBD1. The C-terminal region in
hBD3 is packed against the internal domain, which contains
two glutamic acid residues (Glu27 and Glu28), and in fact,
Arg43 interacts with Arg17 of -sheet 1, which also interacts
with Glu27 of -sheet 2. This interaction does not occur in
hBD1. Furthermore, the C-terminal domain (8 amino acids) of
hBD3 has more positive charges (net charge, 6) than the
C-terminal domain (5 amino acids) of hBD1 (net charge, 2).
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The charged residues in the internal domain between the third
and the fourth Cys residues also differ between hBD3 and
hBD1. In particular, hBD3 has two Glu and two Lys residues,
whereas hBD1 has only one Lys residue. Finally, hBD3 has
more net total positive charges (11) than hBD1 (4).
Design and synthesis of novel peptides. To produce variants
that contain the regions described above in different combina-
tions, we synthesized eight analogs (the hBD1 and hBD3 re-
gions that have been changed in the analogs are underlined
or evidenced in color in Fig. 1B and C, respectively). The
analogs synthesized (Fig. 1B) have net charges ranging from
3 to 12. All peptides were obtained from solid-phase
peptide synthesis, and the yields of the purified linear prod-
ucts were good (approximately 25 to 30%). Mass spectrom-
etry revealed the formation of three disulfide bonds in all
the analogs, as in the wild-type defensins.
FIG. 1. (A) Superimposition of hBD1 (red) and hBD3 (blue) polypeptide chains. The side chains of some charged residues (blue) and
disulfide bonds (orange and yellow) are also shown. (B) Sequence alignments and net charges of hBD1, hBD3, and synthetic analogs. The
disulfide connectivities among the consecutively numbered cysteines are shown at the top. The hBD1 and hBD3 regions that have been
substituted in the analogs and that are underlined are N (amino-terminal peptide segment), I (internal domain between Cys3 and Cys4), and
C (C-terminal peptide segment). The net charges for these segments are reported on the right. Conserved residues are marked by the vertical
green bands; secondary structure elements are shown at the bottom in brown (alpha helix) and yellow (beta sheet). The colored segments
of sequences derive from hBD1 (red) or hBD3 (blue). (C) The colored drawings in the boxed bars indicate the regions exchanged between
hBD1 and hBD3.
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All peptides were dissolved in PBS (at pH 7.4) immediately
before the start of the experiments. To verify that the dissolved
peptides did not undergo any oxidation process before the
assays, we analyzed the reduced hBD1 dissolved in PBS at
times 0 and 30 min by RP-HPLC (Fig. 2). No oxidation oc-
curred during the observation period.
Circular dichroism measurements. We probed the struc-
tures of hBD1 and hBD3 by CD spectroscopy in an aqueous
buffer and in the presence of the organic modifier TFE (Fig.
3A to D). The spectra of the reduced peptides differed greatly
under the two conditions. The spectra in buffer were typical of
a random coil conformation, whereas in the presence of TFE,
there was a broad negative band at about 205 to 210 nm and a
small negative shoulder at about 220 nm. The negative band at
205 to 210 nm indicates a -sheet conformation. On the con-
trary, the spectra of the oxidized peptides in buffer and in TFE
(Fig. 3B and D) are very similar, which confirms that the fold-
ing of oxidized hBD1 and hBD3 is mainly stabilized by the
three disulfide bonds. The TFE spectra of the reduced and the
oxidized forms are very similar. Our results confirm that, be-
cause of the absence of disulfide bridges, the reduced peptides
have a less constrained structure than the oxidized peptides;
however, the reduced peptides appear to fold correctly in the
presence of an organic modifier. We also probed the structures
of the reduced peptides 1C and 3I (Fig. 3E and F), which were
the most active analogs in the antibacterial experiments; the
change in the folding of the two peptides occurred in the
presence of an organic modifier.
Antibacterial activities of hBD1 and hBD3 and their ana-
logs. We tested the antibacterial activities of the hBD1 and
hBD3 peptides in both their reduced and their oxidized forms.
The antibacterial activities of reduced and oxidized hBD1
against P. aeruginosa were superimposable (Fig. 4A). The same
result was obtained with both reduced and oxidized hBD3
(data not shown). Again, the results were similar when hBD1
and hBD3 were tested against E. coli and E. faecalis (data not
shown). Therefore, in all subsequent experiments, we used
only the reduced forms of hBD1 and hBD3 and their analogs.
FIG. 2. Reduced hBD3 was dissolved in PBS (pH 7.4) and analyzed by RP-HPLC at times (t) of 0 and 30 min with a linear gradient of 10 to
50% acetonitrile over 15 min. Abs, absorbance.
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The MICs of hBD1, hBD3, and their analogs were deter-
mined by conventional broth microdilution assays. The MIC
values ranged from 12.5 to 25.0 M for all the microorganisms
tested. Peptides hBD1, hBD3, 3N, 1C, 3I, and 1CI (12.5 M)
exerted strong antibacterial effects against P. aeruginosa, E.
coli, and E. faecalis.
The antibacterial activities of hBD1, hBD3, and their ana-
logs against P. aeruginosa, E. coli, and E. faecalis, expressed as
the percentage of CFU killed, are reported in Fig. 5A, B, and
C, respectively. Two concentrations of each peptide (2.5 and
12.5 M) and four concentrations of NaCl (0, 50, 100, and 200
mM) were used.
As reported in Fig. 5A, at a concentration of 2.5 M, the
antibacterial activity of hBD1 against P. aeruginosa was
strongly inhibited at an NaCl concentration as low as 50 mM
(paired t test versus the result for medium without NaCl, P 
0.001).
On the contrary, the activity of hBD3 against P. aeruginosa
was not inhibited by 50 mM NaCl; was slightly, albeit signifi-
cantly, inhibited by 100 mM NaCl (paired t test versus the
result for hBD3 activity at 0 mM NaCl, P  0.01), and was
greatly inhibited by 200 mM NaCl (paired t test versus the
result for hBD3 activity at 0 mM NaCl, P  0.001). At a
concentration of 12.5 M, the activity of hBD1 was again
FIG. 3. Circular dichroism spectra in HEPES buffer in the presence or absence of 40% TFE of reduced (A) and oxidized (B) hBD1,
reduced (C) and oxidized (D) hBD3, reduced 1C (E), and reduced 3I (F).
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inhibited by 50 mM NaCl (paired t test versus the result for
medium without NaCl, P  0.001), while the antibacterial
activity of hBD3 against P. aeruginosa was significantly inhib-
ited only by 200 mM NaCl (paired t test versus the result for
hBD3 activity at 0 mM NaCl, P  0.001). Similarly, in the
presence of 200 mM NaCl, the antibacterial activity of hBD3 at
2.5 and 12.5 M against E. coli (Fig. 5B) and E. faecalis (Fig.
5C) was significantly inhibited compared to its activity in the
absence of NaCl.
When hBD3 is considered to be the reference wild-type
defensin because it had greater antibacterial activity than
hBD1, the most active analogs against P. aeruginosa were 3N,
1C, and 3I (Fig. 5A). These peptides maintained good anti-
bacterial activity at increasing NaCl concentrations and were
the most active peptides at 200 mM NaCl. This can be seen
more clearly in Fig. 4B, in which we compare the percentages
of CFU killed by 3N, 1C, and 3I with the percentage killed by
hBD3. As shown in Fig. 5A, analog 1CI also displayed good
antibacterial activity at 200 mM NaCl, but it was less active
than hBD3 at 50 and 100 mM NaCl. The other analogs,
namely, 1N, 1I, and 3CI, had low levels of activity at increasing
NaCl concentrations, particularly at 200 mM NaCl. At a pep-
tide concentration of 12.5 M, the pattern of antibacterial
activity against P. aeruginosa was similar to that at a peptide
concentration of 2.5 M, which shows that the three analogs
(3N, IC, and 3I) also had the highest levels of activity against
P. aeruginosa at 200 mM NaCl. It is interesting to note that at
200 mM NaCl, the antibacterial activities of the three peptides
were much higher (90% or more) than the antibacterial activity
of hBD3 (10.4%).
Figures 5B and C show the activities of the analogs against
the other bacterial strains, i.e., E. coli and E. faecalis, respec-
tively. Again, peptides 3N, 1C, and 3I exerted the highest levels
of antibacterial activity also at high NaCl concentrations; this
was true at peptide concentrations of both 2.5 and 12.5 M.
Figure 5 also shows that the trend of the activities of all wild-
type peptides and analogs at increasing NaCl concentrations
against the three bacteria were similar; however, there was
some difference in the level of activity. For example, as shown
in Fig. 4C, at 200 mM NaCl, hBD3 at a concentration of 2.5
M displayed a significantly higher level of activity against E.
coli and E. faecalis than against P. aeruginosa (paired t test, P
0.01 in both cases).
Antiviral activities of hBD1 and hBD3 and their analogs
against herpes simplex virus type 1. We first evaluated, using
the lactate dehydrogenase assay, the viabilities of cells exposed
to the wild-type defensins and to their analogs and found that
they did not differ significantly from those of cells not exposed
to defensins (data not shown). We then compared the antiviral
effects of reduced and oxidized hBD1 and found no difference
between the two forms (Fig. 6A). Therefore, we used the
reduced forms of hBD1 and hBD3 and of analogs 1N, 3N, 1C,
3I, and 3C in all subsequent experiments.
All peptides inhibited HSV infectivity in a dose-dependent
manner (Fig. 6B). The most active peptides were hBD3 (no
residual infectivity at 50 M), analog 3N (10% residual infec-
tivity at 50 M), analog 1C (34% residual infectivity at 50 M),
and analog 3I (27% residual infectivity at 50 M). The three
other peptides tested (hBD1, 1N, and 3C) displayed lower
levels of antiviral activity at 50 M. HSV-1 infectivity was not
inhibited in experiments carried out without peptide.
We next evaluated the antiviral activities of wild-type pep-
tides and their analogs in coexposure experiments (with cell,
virus, and peptide at zero time), virus preexposure experiments
(virus plus peptide before cell infection), and cell preexposure
experiments (cell plus peptide before virus infection). This
allowed us to evaluate if and in which phase the peptides could
inhibit virus infectivity. We choose a peptide concentration of
20 M; at this concentration, each of the peptides tested in-
hibited HSV infectivity (Fig. 6B), albeit with different degrees
of efficacy. The most efficient peptides were hBD3 and analog
3N under all three experimental conditions (Fig. 6C); analogs
1C and 3I were particularly active when they were tested in the
cell preexposure experiment. The other peptides (hBD1, 1N,
and 3C) displayed lower levels of antiviral activity than hBD3
(unpaired two-tailed t test with significance set at 0.05). Viral
FIG. 4. Antibacterial activity at increasing NaCl concentrations of re-
duced and oxidized hBD1 (2.5 M) against P. aeruginosa (A); of analogs
3N, 1C, and 3I (2.5 M) against P. aeruginosa (B); and of hBD3 (2.5 M)
against P. aeruginosa, E. faecalis, and E. coli (C). Error bars show the SDs
of experiments performed in triplicate.
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infectivity was not inhibited in experiments carried out without
peptide.
Chemotactic activities of hBD1 and hBD3 and their analogs.
To better define the antimicrobial activities of hBD1 and
hBD3 and their analogs, we evaluated their chemotactic effects
against neutrophils and monocytes at various NaCl concentra-
tions. We first carried out the lactate dehydrogenase cytotox-
icity assay to exclude the possibility that the two hBDs and
their analogs cause monocyte and neutrophil cytolysis. We
then evaluated the chemotactic effects of hBD1 and hBD3 on
neutrophils and monocytes in the presence of 100, 150, and 200
mM NaCl, with 100 mM NaCl being the minimal concentra-
FIG. 5. Activities (means and SDs of three replicates for each assay) of wild-type hBD1 and hBD3 and their novel analogs against P. aeruginosa
(A), E. coli (B), and E. faecalis (C) at different NaCl concentrations.
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tion required for the assay medium. As shown in Table 1, NaCl
concentrations of 150 and 200 mM did not influence the che-
motactic effect of hBD1 on neutrophils compared with the
effect at 100 mM. NaCl concentrations of 150 and 200 mM
significantly reduced the chemotactic effect of hBD3 on neu-
trophils but significantly increased the chemotactic effects of
both hBD1 and hBD3 on monocytes (Table 1). However, at
200 mM NaCl, the chemotactic effects of both wild-type de-
fensins on monocytes were comparable to the effect obtained
at 100 mM NaCl, which indicates that the optimal NaCl con-
centration for monocyte chemotaxis is 150 mM NaCl.
Table 2 shows the chemotactic effects of all peptides on
neutrophils and monocytes, irrespective of the NaCl concen-
tration. All peptides were chemotactic for neutrophils, and the
effect was greater at a peptide concentration of 1.25 M than
at higher concentrations. Therefore, we compared the chemo-
tactic activity of each peptide at 1.25 M to that of 1.25 M
hBD1 using the two-tailed unpaired t test with significance set
at 0.05. Wild-type hBD1 and hBD3 and their analogs were
chemotactic for neutrophils, albeit with some slight, not signif-
icant, differences in the magnitudes of their effects. At concen-
trations above 1.25 M, the chemotactic effects of hBD1 and
hBD3 on neutrophils were dramatically reduced (Table 2).
Hence, we did not make any comparison between the analog
peptides at a concentration of 2.5 M.
Similarly, all peptides were chemotactic for monocytes when
they were tested at a concentration of 1.25 M (Table 2). In
this case, we also compared the chemotactic activity of each
analog at 1.25 M to that of 1.25 M hBD1. The chemotactic
activity of peptide 1C was significantly lower than that of hBD1
(unpaired t test, P  0.001). Wild-type hBD3 was significantly
more chemotactic than hBD1 (unpaired t test, P  0.001). The
activities of the other molecules were comparable to the activ-
ity of hBD1. At a concentration above 1.25 M, there was no
further increase in chemotactic activity (data not shown).
FIG. 6. Antiviral activities, tested with herpes simplex virus type 1,
of reduced and oxidized wild-type hBD1 with different peptide con-
centrations (A); antiviral activities (cell, virus, and peptide at zero
time) with increasing concentrations of hBD1 and hBD3 and analogs
1C, 1N, 3C, 3N, and 3I (B); and antiviral activities of peptides hBD1
and hBD3 and analogs 1C, 1N, 3C, 3N, and 3I (20 M) after different
treatments (see also Materials and Methods): coexposure, cell, virus,
and peptide at time zero; virus pretreatment, virus and peptide before
cell infection; and cell preexposure, cell and peptide before virus in-
fection (C). Error bars show the SDs of experiments performed in
triplicate.
TABLE 1. Chemotactic activities of wild-type hBD1 and hBD3
against neutrophils and monocytes at different
NaCl concentrationsa
hBD NaCl concn(mM)
% migrating
neutrophils
% migrating
monocytes
hBD1 100 13.5  3.4 12.5  2.8
150 12.5  1.8 24.3  2.8b
200 11.2  2.8 10.1  1.4
hBD3 100 8.7  2.6 7.3  2.1
150 5.4  2.1b 12.8  3.2b
200 5.0  1.0b 7.2  1.6
a The peptide concentration was 1.25 M. The percentage of migrating cells is
in reference to the total number of cells in each assay. The data represent the
means  SDs of three replicates.
b Significantly different (two-tailed unpaired t test, P  0.05) from the activity
of the same molecule against the same cells at 100 mM NaCl.
TABLE 2. Chemotactic activities of wild-type hBD1 and hBD3 and
analogs against neutrophils and monocytesa
BD
% migrating neutrophils
at peptide concn of:
% migrating
monocytes at
peptide concn of
1.25 M1.25 M 2.5 M 12.5 M
hBD1 13.5  3.4 5.6  2.8 4.3  2.2 12.5  2.8
hBD3 8.7  2.6 6.2  2.4 4.9  2.1 24.3  3.1b
1N 10.4  3.3 10.8  3.3 3.2  2.1 12.6  2.3
3N 11.2  3.8 6.7  3.9 1.5  0.9 Not tested
1C 12.8  3.1 8.9  3.5 3.9  1.5 1.27  0.48b
1I 9.8  4.3 9.4  4.2 3.5  2.2 10.3  2.3
3I Not tested Not tested Not tested 13.6  2.9
1CI 6.3  2.9 0.0b 0.0b 8.6  2.7
3CI 15.5  3.6 11.4  3.8 3.1  1.0 8.4  2.0
a The percentage of migrating cells is in reference to the total number of cells
in each assay. Data are means  SDs for three replicates.
b Significantly different (two-tailed unpaired t test, P  0.05) from the activity
of wild-type hBD1.
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DISCUSSION
The quest to exploit the antimicrobial activity of beta-de-
fensins is hampered by their salt sensitivity. We have designed
analogs of hBD1 and hBD3 that could have therapeutically
meaningful properties.
There is some debate about whether oxidized or reduced
molecules should be used to evaluate the antimicrobial activ-
ities of hBDs (32). In our hands, the reduced and oxidized
forms of hBDs displayed the same antimicrobial activity. This
finding is particularly interesting, considering that the three-
disulfide-bond structure of hBDs is highly conserved (19). Our
findings are in agreement with those of Hoover et al. (11), who
showed that beta-defensins without disulfide bonds exert effi-
cient antibacterial activity even at high salt concentrations. The
latter observation is also in line with the findings described in
a recent report that an hBD3 analog in which the six cysteines
had been replaced with alanine residues maintained the strong
antibacterial activity of the wild-type molecule (32). Defensins
lack a distinct hydrophobic core, and thus, their folding is
stabilized mainly by the presence of the three disulfide bonds.
A previous report also indicated that linear analogs of hBD3
(1) have significantly higher levels of antimicrobial activity due
to the increased structural flexibility of the linear forms. Al-
though the mechanism whereby defensins exert their effect has
yet to be established, it certainly involves contact with and
permeabilization of the cell membrane through one of two
models: the carpet model (several molecules sit on the surface
of the cell) and the barrel stave model (the peptide oligomer-
izes and forms a multimeric pore in the cell membrane, thereby
causing leakage of the cell contents). The CD spectra in buffer
and in the presence of TFE of hBD1 and hBD3 in the reduced
and oxidized forms indicate that the reduced forms of hBDs
assume the correct folding and disulfide pattern, once they are
placed in a solvent that mimics the membrane bilayer; thus,
our results support the hypothesis that the defensins may as-
sume the correct folding once they are in contact with the
membrane bilayer. Therefore, our finding that the antimicro-
bial activity of hBD1 does not differ between the oxidized and
the reduced forms suggests that either form may be used to
evaluate their properties.
Wild-type hBD1 and hBD3 and their analogs exerted anti-
bacterial activity over the same concentration ranges (2.5 to
12.5 M, i.e., about 10 to 50 g/ml) and at the same incubation
time (2 h) found in previous hBD studies (16, 17, 23, 24, 30,
36). The antibacterial activity of hBD1 was inhibited by 50 mM
NaCl, in agreement with previously published results (9),
whereas the antibacterial activity of hBD3 was inhibited only
by 200 mM NaCl. The latter observation contrasts with the
notion that hBD3 is salt resistant, which emerged from studies
that measured the activity of hBD3 in the presence of up to 150
mM NaCl (23, 30). Our study is the first to evaluate the anti-
microbial activity of hBD3 at an NaCl concentration that is
close to the mean concentration (182 mM) observed in the
respiratory layer of patients with CF (29). Besides the fact that
high NaCl levels in the airways of patients with CF inhibit the
activity of hBDs (5, 9, 33), it is also not easy to eradicate
respiratory infections in patients with CF because of the emer-
gence of antibiotic resistance after long-term treatment (21).
These considerations reinforce the need for more effective
analogs.
Among the novel analogs that we synthesized in this study,
the removal of the N-terminal domain of hBD3 (analog 3N)
presumably changed the structure into a more compact con-
formation that would allow a more efficient interaction of the
peptide with the bacterial surface even at the highest NaCl
concentration tested. In fact, analog 1N (constituted by the
hBD1 sequence plus the first 6 amino acids of the hBD3 ter-
minus) had lower levels of antibacterial activity than hBD1 in
the absence of salt. This result is in agreement with the low
level of activity against E. coli and Staphylococcus aureus re-
ported for a short peptide that contained the 17 N-terminal
amino acids of hBD3 (13). More recently, a peptide of only 23
N-terminal amino acids of mouse beta-defensin 3 was found to
exert strong activity against P. aeruginosa and S. aureus (22).
However, it is not meaningful to compare these data with our
results, given the homology of less than 70% with the human
peptide.
Analog 1C (constituted by hBD1 and the C terminus of
hBD3) had higher levels of antibacterial activity than the wild-
type peptides at high NaCl levels, which suggests that the
hBD3 C terminus is fundamental for antibacterial activity at
high ionic strength. Therefore, it appears that the C-terminal
region of hBD3 (which elongates the beta-3 structure of the
defensin, thus making the molecule more compact) is critical
for antibacterial activity at high NaCl concentrations. Interest-
ingly, analogs spanning the C-terminal region of hBD1 to
hBD3 were recently found to exert antifungal activity at vari-
ous NaCl concentrations (14).
A third region that modulates antibacterial activity is the
internal region of hBD1, as indicated by the high level of
antibacterial activity of analog 3I (which is constituted by
hBD3 with the internal region of hBD1) at high ionic strength.
On the contrary, the two negatively charged Glu residues in the
internal region of hBD3 impair efficient contact with the target
surface, as indicated by the scarce antibacterial activity of an-
alog 1I, in which the internal sequence of hBD1 was replaced
with the hBD3 internal sequence.
The results obtained with the hBD analogs bearing two
substitutions each confirm the results described above. In fact,
analog 1CI, which contains the internal and the C-terminal
regions of hBD3, maintains some antibacterial activity at high
NaCl levels. Thus, the absence of the N terminus of hBD3,
together with the presence of the C-terminal regions of hBD3,
presumably makes the molecule more compact and also
allows H bonding between Arg43 and Glu27, which occurs
in wild-type hBD3. Analog 3CI contains the internal region
and the C terminus of hBD1 but not the C terminus of hBD3
and therefore lacks the high charge and the more compact
conformation conferred by those regions. Consequently, an-
alog 3CI has a low level of antibacterial activity and low salt
resistance.
Several novel findings emerged from our study of the anti-
viral activities of beta-defensins against HSV-1. At a concen-
tration of 50 M, hBD3 and the 3N analog greatly inhibited
virus infectivity, whereas 1C inhibited infectivity by about 60%.
This finding is in agreement with data obtained in studies with
HIV (3, 34). Antiviral activity is influenced by the same do-
mains that modulate antibacterial activity. In fact, as emerges
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particularly from the virus preexposure experiments, the dele-
tion of the N-terminal part in analog 3N results in an increase
in antiviral activity, whereas analog 1N, which includes the
N-terminal part, has poor antiviral activity. Similarly, the
C-terminal domain of hBD3 enhances antiviral activity
(note the lower level of activity of analog 3C compared with
that of wild-type hBD3). On the basis of our findings, it
appears that defensins, particularly thanks to some of their
domains, exert potent antiviral activity. We also suggest that
these two regions (the N- and C-terminal domains of hBD3)
influence antiviral activity via the same mechanisms postu-
lated for antibacterial activity (8). Indeed, the inhibitory
activities of defensins differ among viruses, most likely de-
pending on the features of the viral envelope structure,
including its lipid composition (8).
Regarding the issue of the chemotactic effects of hBD1 (4,
18) and hBD3 (35), here we show that both hBD1 and hBD3
are chemotactic for neutrophils, irrespective of the NaCl con-
centration, whereas the chemotactic activity of hBD1 against
monocytes was enhanced when the salt concentration was in-
creased from 100 to 150 mM. Furthermore, on the basis of our
overall data, it appears that the N-terminal, internal, and C-
terminal domains do not affect the chemotactic activity against
neutrophils and that hBD3 is particularly active against mono-
cytes.
In conclusion, we designed and synthesized analogs of the
innate immunity peptides hBD1 and hBD3. We then investi-
gated their antibacterial, antiviral, and chemotactic activities
and their salt resistance. Consequently, we were able to
identify the peptides and/or their domains that exert the
most potent antibacterial, antiviral, and chemotactic activi-
ties. Two of these peptides, i.e., analogs 1C and 3I, are the
best suited, in terms of maximizing antimicrobial activity in
the presence of high NaCl concentrations, and may be of
benefit for the treatment of chronic infections like those
observed in patients with CF.
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